title: Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.
authors.affiliation: Department of Pathology, University of Arizona, P.O. Box 24-5043, 1501 N Campbell Ave, Tucson, AZ, 85724, USA.
authors.forename: Samantha
authors.initials: S
authors.lastname: Kendrick
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Rimsza
authors.affiliation: Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
authors.forename: David W
authors.initials: DW
authors.lastname: Scott
authors.affiliation: Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: Graham W
authors.initials: GW
authors.lastname: Slack
authors.affiliation: Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: Pedro
authors.initials: P
authors.lastname: Farinha
authors.affiliation: Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: King L
authors.initials: KL
authors.lastname: Tan
authors.affiliation: University of Arizona Cancer Center, Tucson, AZ, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Persky
authors.affiliation: University of Arizona Cancer Center, Tucson, AZ, USA.
authors.forename: Soham
authors.initials: S
authors.lastname: Puvvada
authors.affiliation: Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Connors
authors.affiliation: Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
authors.forename: Laurie
authors.initials: L
authors.lastname: Sehn
authors.affiliation: Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.|Department of Pathology, British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: Randy D
authors.initials: RD
authors.lastname: Gascoyne
authors.affiliation: Department of Pathology, University of Arizona, P.O. Box 24-5043, 1501 N Campbell Ave, Tucson, AZ, 85724, USA. schmelz@pathology.arizona.edu.
authors.forename: Monika
authors.identifier: http://orcid.org/0000-0001-6771-4153
authors.initials: M
authors.lastname: Schmelz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003593:Cytoplasm / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000949:Histocompatibility Antigens Class II